Literature DB >> 26239836

Subpath analysis of each subtype of head and neck cancer based on the regulatory relationship between miRNAs and biological pathways.

Fengwei An1, Zhiqiang Zhang2, Ming Xia3, Lijun Xing4.   

Abstract

The aim of the present study was to explore the potential mechanisms involved in each subtype of head and neck squamous cell carcinoma (HNSCC) via subpath analysis and to investigate their relevance in the prevention of HNSCC. Gene expression profiles of GSE6631 and GSE39366 containing 44 and 168 HNSCC samples, respectively, were downloaded from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) from samples in GSE6631 and GSE393666 were screened using the Detection of Imbalanced Differential Signal (DIDS) method respectively. DEGs in GSE39366 were matched with the DEGs in GSE6631 and were used to classify the subtypes of HNSCC based on hierarchical clustering analysis. Furthermore, DEGs were separated into different subtypes and then the pathway information was analyzed. The regulated miRNAs for the DEGs in each subtype were analyzed to select the significant subpaths. Totally, 1,095 DEGs from GSE6631 and 2,528 DEGs from GSE39366 were screened. Samples in GSE39366 were separated into four subtypes. Specific genes in each subtype and DEGs in the common gene set involved in a variety of pathways were identified. In addition, the significant miRNA-target-pathway subpath of each subtype of HNSCC and the common gene set of HNSCC were also enriched. Our data suggest that human papillomavirus (HPV) is positively correlated with HNSCC in subtype 2. Several miRNAs (miRLet-7A, miR-1, miR-206, miR-153, miR-519A and miR-506) and their target genes (CYP46A1, BPNT1, MCM7 and COL5A1) are crucial for HNSCC prevention via different pathways and may provide further knowledge of the mechanisms involved in the progression of HNSCC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26239836     DOI: 10.3892/or.2015.4150

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Dynamic edge-based biomarker non-invasively predicts hepatocellular carcinoma with hepatitis B virus infection for individual patients based on blood testing.

Authors:  Yiyu Lu; Zhaoyuan Fang; Meiyi Li; Qian Chen; Tao Zeng; Lina Lu; Qilong Chen; Hui Zhang; Qianmei Zhou; Yan Sun; Xuefeng Xue; Yiyang Hu; Luonan Chen; Shibing Su
Journal:  J Mol Cell Biol       Date:  2019-08-19       Impact factor: 6.216

2.  The Highly Expressed IFIT1 in Nasopharyngeal Carcinoma Enhances Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma Cells.

Authors:  Xuan Wu; Liping Lin; Fengrui Zhou; Shaokang Yu; Minhua Chen; Shubin Wang
Journal:  Mol Biotechnol       Date:  2022-01-17       Impact factor: 2.860

3.  MicroRNA-519a promotes proliferation and inhibits apoptosis of hepatocellular carcinoma cells by targeting FOXF2.

Authors:  Junwei Shao; Jun Cao; Yong Liu; Hongliang Mei; Yang Zhang; Weitian Xu
Journal:  FEBS Open Bio       Date:  2015-11-07       Impact factor: 2.693

4.  The Hypoxia-Related Gene COL5A1 Is a Prognostic and Immunological Biomarker for Multiple Human Tumors.

Authors:  Hua Zhu; Xinyao Hu; Shi Feng; Zhihong Jian; Ximing Xu; Lijuan Gu; Xiaoxing Xiong
Journal:  Oxid Med Cell Longev       Date:  2022-01-17       Impact factor: 6.543

5.  Synthetic Evaluation of MicroRNA-1-3p Expression in Head and Neck Squamous Cell Carcinoma Based on Microarray Chips and MicroRNA Sequencing.

Authors:  Baoju Wang; Zhan Wu; Yubing Chen; Mingjiang Liu; Hu Jin; Bo Peng; Luo Dai; Sifan Wang; Hao Xing
Journal:  Biomed Res Int       Date:  2021-08-24       Impact factor: 3.411

Review 6.  The emerging role of miR-506 in cancer.

Authors:  Jian Li; Jingfang Ju; Bing Ni; Huaizhi Wang
Journal:  Oncotarget       Date:  2016-09-20

7.  Prospective molecular mechanism of COL5A1 in breast cancer based on a microarray, RNA sequencing and immunohistochemistry.

Authors:  Mei Wu; Qi Sun; Chao-Hua Mo; Jin-Shu Pang; Jia-Yin Hou; Ling-Ling Pang; Hui-Ping Lu; Yi-Wu Dang; Su-Jie Fang; Deng Tang; Gang Chen; Zhen-Bo Feng
Journal:  Oncol Rep       Date:  2019-05-03       Impact factor: 3.906

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.